U.S. Markets close in 11 mins.

Sanofi (SNY)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
47.71-0.35 (-0.72%)
As of 3:48PM EDT. Market open.
People also watch
Full screen
Previous Close48.06
Bid47.70 x 100
Ask47.71 x 1000
Day's Range47.34 - 47.88
52 Week Range36.81 - 50.24
Avg. Volume1,941,952
Market Cap111.62B
PE Ratio (TTM)11.54
Earnings DateN/A
Dividend & Yield1.64 (3.41%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod
    Zacks7 hours ago

    Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

    Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

  • Reuters8 hours ago

    EU follows U.S. in backing Sanofi, Regeneron eczema drug

    The European Medicines Agency on Friday recommended approval of Regeneron Pharmaceuticals and Sanofi's new drug Dupixent for atopic dermatitis, a product many analysts see as the most important growth driver for the two companies. Recommendations from the agency's expert committee on new drugs are normally endorsed by the European Commission within a couple of months. Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, often unbearable, itching.

  • Reutersyesterday

    FDA tentatively approves Merck's copycat of Sanofi's Lantus

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.